TREZZI M.

Last name: TREZZI M.

2012 (v1)

Publication

Metadata-only

96 week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: A multicentre Italian experience

Capetti A. Landonio S. Meraviglia P.

Background: Long term efficacy of raltegravir (RAL)-including regimens in highly pre-treated HIV-1-infected patients has been demonstrated in registration trials. However, few studies have assessed durability in routine clinical settings. Methods: Antiretroviral treatment-experienced patients initiating a RAL-containing salvage regimen were...

Uploaded on: April 14, 2023
2019 (v1)

Publication

Metadata-only

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study

Rossetti B. Gagliardini R. Sterrantino G.

No description

Uploaded on: April 14, 2023
2017 (v1)

Publication

Metadata-only

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial

Rossetti B. Gagliardini R. Meini G.

Objectives: Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48. Methods: Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were randomized 1:1 to maraviroc with darunavir/ritonavir qd (study arm) or continue current ART (continuation...

Uploaded on: April 14, 2023

TREZZI M.

Recent uploads